PepGen (PEPG) Competitors $4.41 +0.09 (+2.08%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PEPG vs. SVRA, ANNX, MBX, ABVX, IRWD, ORGO, ATXS, CRVS, PHAR, and IGMSShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Savara (SVRA), Annexon (ANNX), MBX Biosciences (MBX), ABIVAX Société Anonyme (ABVX), Ironwood Pharmaceuticals (IRWD), Organogenesis (ORGO), Astria Therapeutics (ATXS), Corvus Pharmaceuticals (CRVS), Pharming Group (PHAR), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry. PepGen vs. Savara Annexon MBX Biosciences ABIVAX Société Anonyme Ironwood Pharmaceuticals Organogenesis Astria Therapeutics Corvus Pharmaceuticals Pharming Group IGM Biosciences Savara (NASDAQ:SVRA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has stronger valuation & earnings, SVRA or PEPG? Savara is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$54.70M-$0.43-7.81PepGenN/AN/A-$78.63M-$2.98-1.48 Do analysts prefer SVRA or PEPG? Savara currently has a consensus target price of $10.17, indicating a potential upside of 202.58%. PepGen has a consensus target price of $14.67, indicating a potential upside of 232.58%. Given PepGen's higher probable upside, analysts plainly believe PepGen is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83PepGen 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is SVRA or PEPG more profitable? Savara's return on equity of -58.89% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -58.89% -46.44% PepGen N/A -60.17%-48.88% Does the media prefer SVRA or PEPG? In the previous week, Savara had 4 more articles in the media than PepGen. MarketBeat recorded 10 mentions for Savara and 6 mentions for PepGen. Savara's average media sentiment score of 0.80 beat PepGen's score of -0.11 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor SVRA or PEPG? Savara received 280 more outperform votes than PepGen when rated by MarketBeat users. However, 81.82% of users gave PepGen an outperform vote while only 66.67% of users gave Savara an outperform vote. CompanyUnderperformOutperformSavaraOutperform Votes29866.67% Underperform Votes14933.33% PepGenOutperform Votes1881.82% Underperform Votes418.18% Do insiders & institutionals have more ownership in SVRA or PEPG? 87.9% of Savara shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 5.1% of Savara shares are held by insiders. Comparatively, 4.6% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, SVRA or PEPG? Savara has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. SummarySavara beats PepGen on 11 of the 15 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.77M$6.59B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-1.485.9576.4514.80Price / SalesN/A357.081,246.7887.32Price / CashN/A53.8240.9036.92Price / Book1.0510.617.196.55Net Income-$78.63M$153.27M$119.54M$226.22M7 Day Performance7.04%3.97%2.12%3.77%1 Month Performance-49.31%-6.72%-2.43%4.64%1 Year Performance-5.57%33.26%34.52%29.21% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.2221 of 5 stars$4.41+2.1%$14.67+232.6%-5.6%$143.77MN/A-1.4872News CoverageSVRASavara2.5133 of 5 stars$3.25+3.8%$10.17+213.3%-7.4%$556.91MN/A-7.55N/AANNXAnnexon2.7874 of 5 stars$5.22+1.2%$15.80+202.5%+104.8%$556.69MN/A-5.1060MBXMBX Biosciences2.1416 of 5 stars$16.51+1.7%$37.25+125.6%N/A$551.76MN/A0.0036ABVXABIVAX Société Anonyme2.8838 of 5 stars$8.65-2.4%$39.80+360.1%-13.2%$547.46MN/A0.0061IRWDIronwood Pharmaceuticals4.3031 of 5 stars$3.34-5.1%$10.40+211.4%-63.8%$534.50M$442.73M-117.33220ORGOOrganogenesis4.1251 of 5 stars$4.02+1.3%$5.33+32.7%+56.4%$532.97M$433.14M-66.17950ATXSAstria Therapeutics1.9047 of 5 stars$9.41-1.8%$25.60+172.1%+117.3%$531.00MN/A-4.5030CRVSCorvus Pharmaceuticals2.5199 of 5 stars$9.01+9.3%$12.83+42.4%+534.8%$529.48MN/A-9.6930High Trading VolumePHARPharming Group2.189 of 5 stars$7.80+1.6%$33.50+329.5%-35.4%$529.07M$245.32M-30.00382Positive NewsHigh Trading VolumeIGMSIGM Biosciences4.6909 of 5 stars$8.89-9.0%$16.13+81.4%+64.0%$528.60M$2.13M-2.44190Positive NewsGap Down Related Companies and Tools Related Companies Savara Alternatives Annexon Alternatives MBX Biosciences Alternatives ABIVAX Société Anonyme Alternatives Ironwood Pharmaceuticals Alternatives Organogenesis Alternatives Astria Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Pharming Group Alternatives IGM Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PEPG) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEPG Stock Alerts